Kimber, Catherine http://orcid.org/0000-0001-9994-8640
Cox, Sharon
Frings, Daniel
Albery, Ian P.
Dawkins, Lynne
Funding for this research was provided by:
Cancer Research UK (25855)
Article History
Received: 16 December 2020
Accepted: 22 August 2021
First Online: 8 September 2021
Declarations
:
: The study received full ethical approval from London South Bank University’s ethics committee (approval date: 4/07/2018; reference SAS1815). Participants provided electronic informed consent online prior to the start of the study. All data were anonymised from the outset.
: All participants provided consent for publication electronically prior to the start of the study.
: CK has no conflict of interest to declare. SC has provided expert consultancy to providers of UK life insurance and to the pharmaceutical industry relating to the development of smoking cessation products. DF and IA received funding from Allen Carr’s Easyway Ltd (ISRCN number: ISRCTN23584477). The trial was conducted independently, the protocol and analysis plan were both pre-registered and the research team were contractually free to independently publish the results of the trial regardless of the study outcome. IA has also received funding from Gambleaware (2020–2021). This work will be conducted independently, with protocol and analysis plan pre-registered and the research team contractually free to independently publish the results regardless of the study outcome. LD has provided consultancy for the pharmaceutical industry relating to the development of smoking cessation products.